The role of ADAR1 through and beyond its editing activity in cancer

作者：Yue Jiao, Yuqin Xu, Chengbin Liu, Rui Miao, Chunyan Liu, Yilong Wang, Jiao Liu · 发表于：Cell Communication and Signaling · 年份：2024 · DOI：10.1186/s12964-023-01465-x · 被引用次数：23 · 研究领域：RNA regulation and disease、RNA Research and Splicing、RNA modifications and cancer

Adenosine-to-inosine (A-to-I) editing of RNA, catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes, is a prevalent RNA modification in mammals. It has been shown that A-to-I editing plays a critical role in multiple diseases, such as cardiovascular disease, neurological disorder, and particularly cancer. ADARs are the family of enzymes, including ADAR1, ADAR2, and ADAR3, that catalyze the occurrence of A-to-I editing. Notably, A-to-I editing is mainly catalyzed by ADAR1. Given the significance of A-to-I editing in disease development, it is important to unravel the complex roles of ADAR1 in cancer for the development of novel therapeutic interventions.In this review, we briefly describe the progress of research on A-to-I editing and ADARs in cancer, mainly focusing on the role of ADAR1 in cancer from both editing-dependent and independent perspectives. In addition, we also summarized the factors affecting the expression and editing activity of ADAR1 in cancer.